KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Gastroenterology / 2021 / Cilt: 32 - Sayı: 6

Turkish IBD Organization’s Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic

Murat TÖRÜNER
İsmail Hakkı KALKAN
Filiz AKYÜZ
Ahmet TEZEL
Aykut Ferhat ÇELİK
Sayfa
488–492
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2, has resulted in high mortality and morbidity worldwide and is still a growing problem.
📊
Temel Bulgular & Veri:Despite the accumulating evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive treatment.
💡
Sonuç & Katkı:In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2, has resulted in high mortality and morbidity worldwide and is still a growing problem. Inflammatory bowel disease (IBD) is a chronic inflammatory disease for which a substantial number of patients are treated with immunosuppressive medications, either occasionally or long-term. Despite the accumulating evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive treatment. Moreover, following the emergence of several COVID vaccines, there are concerns regarding vaccine effectiveness and possible side effects in such patients. In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic

🔖

Bu Makaleye Atıf Yap

TÖRÜNER, M., KALKAN, İ. H., AKYÜZ, F., TEZEL, A., ÇELİK, A. F. (2021). Turkish IBD Organization’s Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 6, 488–492. https://ajindex.com/articles/410013

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020
  2. 323(11):1061-1069. [CrossRef] 2. Anon, world health organization, dirs.General’s opening remarks at the media briefing on COVID-19. https://www.who.int/dg/spee ches/detail/who-director-general-sopening-rema rks- at -th emedia- briefing-on-covid-19-23-marc h-2020. 2020. 3. Anon. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2020 https://gisanddata.maps.arcgis.com/apps/dashboards/bda 7594740fd40299423467b48e9ecf6. 4. She J, Liu L, Liu W. COVID-19 epidemic: disease characteristics in children. J Med Virol. 2020
  3. 92(7):747-754. [CrossRef] 5. Wang W., Xu Y, Gao R et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020
  4. 323(18):1843-1844. [CrossRef] 6. Huang C., Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020
  5. 395(10223):497-506. [CrossRef] 7. Guan W.J., Ni ZY, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020
  6. 382(18):1708-1720. [CrossRef] 8. Hajifathalian K., Krisko T, Mehta A et al. Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients From New York: clinical implications. Gastroenterology. 2020
  7. 159(3):1137-1140.e2. [CrossRef] 9. Kluytmans-van den Bergh M.F.Q., Buiting AGM, Pas SD et al. Prevalence and clinical presentation of health care workers With symptoms of coronavirus disease 2019 in 2 Dutch hospitals During an early phase of the pandemic. JAMA Netw Open. 2020
  8. 3(5):e209673. [CrossRef] 10. Pan L., Mu M, Yang P et al. Clinical characteristics of COVID-19 patients With digestive symptoms in Hubei, China: A descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020
  9. 115(5):766-773. [CrossRef] 11. Zhou F., Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020
  10. 395(10229):1054-1062. [CrossRef] 12. Zhu N., Zhang D, Wang W et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020
  11. 382(8):727-733. [CrossRef] 13. Chan J.F., Yuan S, Kok KH et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster. Lancet. 202